Welcome ISCT Early Stage Professionals
Re-engineering cell therapy with invariant Natural Killer T (iNKT) cells
An allogeneic, off‑the‑shelf CAR‑iNKT platform now entering first‑in‑human trials in Australia.
OUR PLATFORM
We engineer invariant Natural Killer T (iNKT) cells to deliver a multi-pronged attack against cancer. CAR-iNKT cells have multiple ways to kill cancer cells.
Engineered targeting via the CAR
Natural targeting via the invariant TCR / CD1d axis and NKG2D pathway
Remodulate the tumour microenvironment
Activate T and NK cells
Learn more about our science →
Watch the video below to learn how CAR-iNKT cells work.
OUR PROGRAMS
ALA-101 | Allogeneic CD19-directed CAR-iNKT cells
Targets CD19-positive B cell lymphomas and leukaemias
IND Approved, Ethics Approved, Phase I study initiated in Australia
Due to commence first patient dosing in Q3 CY2026
ALA-105 | Allogeneic CLDN18.2-directed CAR-iNKT cells with IL-12-TM cytokine armouring
Targets CLDN18.2-positive gastric and pancreatic cancers
Utilises novel, proprietary CLDN18.2-targeting CAR and membrane-anchored IL-12 cytokine armouring
Armouring improves cell persistence and durability of the anti-tumour response under high tumour burden
UPCOMING CLINICAL TRIAL
An open label, phase 1 dose escalation trial evaluating the safety, tolerability and preliminary efficacy of ALA-101 in patients with relapsed or refractory lymphomas and leukaemias.
“There is a substantial unmet need for patients with relapsed or refractory haematological cancers, particularly for patients who have exhausted existing treatment options. ALA-101’s iNKT biology, combined with targeted CAR technology, is an innovative platform which addresses some of the challenges associated with existing cell therapies.”
To learn more about our trial, please contact us.
